A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In Patients With Fibromyalgia
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
This study will assess the safety and efficacy of the long-term use of pregabalin at doses up to 450 mg/day in patients with fibromyalgia who have completed 16 weeks of dosing in Study A0081208 (NCT00830167).
| Condition | Intervention | Phase |
|---|---|---|
|
Fibromyalgia |
Drug: pregabalin (Lyrica) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label Extension Safety And Efficacy Study Of Pregabalin (CI-1008) For The Treatment Of Fibromyalgia |
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Up to 53 weeks ] [ Designated as safety issue: Yes ]Any untoward medical occurrence in a participant who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events: those which occurred or worsened after baseline. An AE resulting in any of the following outcomes, was considered to be a serious adverse event: death; lifethreatening; initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect.
- Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit.
Change = mean scores at observation minus mean scores at baseline.
- Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Disturbance at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means greater sleep disturbance.
Change = mean scores at observation minus mean scores at baseline.
- Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Snoring at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms.
Change = mean scores at observation minus mean scores at baseline.
- Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Awaken Short of Breath or With a Headache at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms.
Change = mean scores at observation minus mean scores at baseline.
- Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Sleep Adequacy at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means greater sleep adequacy.
Change = mean scores at observation minus mean scores at baseline.
- Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Quantity of Sleep at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score means greater quantity of sleep.
Change = mean scores at observation minus mean scores at baseline.
- Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Somnolence at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms.
Change = mean scores at observation minus mean scores at baseline.
- Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale - Overall Sleep Problems Index at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
MOS: patient rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score means worse symptoms.
Change = mean scores at observation minus mean scores at baseline.
- Medical Outcomes Study (MOS) Sleep Scale - Optimal Sleep at Endpoint [ Time Frame: Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Number of participants with response = YES if sleep quantity is 7 or 8 hours per night or response = NO if sleep quantity is < 7 hours per night.
- Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Total Scores at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment.
Change = mean FIQ scores at observation minus mean scores at baseline.
- Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) - Subscale Score at Endpoint [ Time Frame: Baseline, Week 52 or Study Discontinuation ] [ Designated as safety issue: No ]
FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment.
Change = mean FIQ scores at observation minus mean scores at baseline.
| Enrollment: | 106 |
| Study Start Date: | July 2009 |
| Study Completion Date: | February 2011 |
| Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: pregabalin (Lyrica) |
Drug: pregabalin (Lyrica)
Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
Other Name: pregabalin (Lyrica)
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients must have met the inclusion criteria for the preceding fibromyalgia Protocol A0081208, and must have received pregabalin/placebo under double-blind conditions.
Exclusion Criteria:
- Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia Study A0081208; which was determined to be related to the study medication by the investigator or the sponsor.
Contacts and Locations| Japan | |
| Pfizer Investigational Site | |
| Yotukaidou, Chiba, Japan | |
| Pfizer Investigational Site | |
| Matuyama-si, Ehime, Japan | |
| Pfizer Investigational Site | |
| Iiduka, Fukuoka, Japan | |
| Pfizer Investigational Site | |
| Kobe, Hyogo, Japan | |
| Pfizer Investigational Site | |
| Kobe, Hyougo, Japan | |
| Pfizer Investigational Site | |
| Mito, Ibaraki, Japan | |
| Pfizer Investigational Site | |
| Morioka, Iwate, Japan | |
| Pfizer Investigational Site | |
| Yokohama, Kanagawa, Japan | |
| Pfizer Investigational Site | |
| Tsu, Mie, Japan | |
| Pfizer Investigational Site | |
| Sendai, Miyagi, Japan | |
| Pfizer Investigational Site | |
| Hiki-gun, Saitama, Japan | |
| Pfizer Investigational Site | |
| Saitama-shi, Saitama, Japan | |
| Pfizer Investigational Site | |
| Shimotsuga-gun, Tochigi, Japan | |
| Pfizer Investigational Site | |
| Chiyoda-ku, Tokyo, Japan | |
| Pfizer Investigational Site | |
| Itabashi-Ku, Tokyo, Japan | |
| Pfizer Investigational Site | |
| Shinagawa-ku, Tokyo, Japan | |
| Pfizer Investigational Site | |
| Nagano, Japan | |
| Pfizer Investigational Site | |
| Oita, Japan | |
| Pfizer Investigational Site | |
| Osaka, Japan | |
| Pfizer Investigational Site | |
| Yokohama, Japan | |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
No publications provided
| Responsible Party: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00830128 History of Changes |
| Other Study ID Numbers: | A0081209 |
| Study First Received: | January 26, 2009 |
| Results First Received: | January 23, 2012 |
| Last Updated: | April 2, 2012 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Additional relevant MeSH terms:
|
Fibromyalgia Myofascial Pain Syndromes Muscular Diseases Musculoskeletal Diseases Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases Pregabalin |
Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anticonvulsants |
ClinicalTrials.gov processed this record on May 21, 2013